



Patient Study Guide

INTRODUCTION

You are being asked to participate in this observational research study because you are an adult who has been identified as being treated with the drug FILSPARI® (sparsentan), which has been approved for use by the Food and Drug Administration (FDA) to reduce levels of protein in the urine (proteinuria) in adults with a kidney disease called primary immunoglobulin A nephropathy (IgAN), and who are at risk of their disease progressing quickly.

The SPARKLER Study is sponsored by Traverre Therapeutics, Inc which is responsible for the initiation and financing of the study. Traverre Therapeutics has contracted United BioSource, LLC (UBC) to manage the day-to-day activities of the study.

This guide will give you important information on what to expect as a participant in the study. Please take the time to read it carefully. This guide is for your own use, so keep it handy throughout the study.

By participating in this study, you are contributing to research that will help advance the understanding of liver injury in patients treated with FILSPARI. Participants like you are partners in this research process—receiving close medical supervision and providing invaluable feedback on your experiences.

Thank you for your participation!

The SPARKLER Study Team



INFORMATION FOR PATIENTS

What is an observational research study?

An observational research study means participants will continue to receive care as decided by their healthcare providers.

Participation in this study will not change treatment or medical care in any way.

What is the purpose of this study?

The purpose of this study is to collect any potential liver-related problems that you may experience while taking FILSPARI. The information that is collected from this observational study will assist in assessing whether FILSPARI may cause Drug-Induced Liver Injury (DILI). It is not known whether FILSPARI causes DILI, which is why it's important to collect the data in this observational study.

What does my participation in this study look like?

Your participation in this study will last approximately 2 years. You will be contacted every 3 months to collect study data including:

- Your enrollment status
- Your primary and secondary contact information
- Medical history
- Demographic characteristics
- Any liver-related problems or issues
- Results of any imaging and laboratory tests associated with liver function

In addition, your doctor will be contacted every 3 months to identify or confirm potential liver-related problems and obtain any missing information that is needed.

Taking part in this study is voluntary. If you decide you do not want to continue participation, you can stop at any time. You will not be penalized or lose any benefits if you decide to end your study participation.

Notes:

Please use this section to write any notes or questions during your participation in the study.

Questions?

If you have questions, please contact the SPARKLER Study team at: **866-974-3979**.

Hours of Operation:

M – F 9:00am – 5:00pm, EST

For more information visit: **www.FILSPARI-registry.com**.